ChiCTR2000033323 版本V1.1 版本创建时间2020/05/28 07:09:17 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000033323 

最近更新日期:

Date of Last Refreshed on:

2020-05-28 07:06:35 

注册时间:

Date of Registration:

2020-05-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

Severe Reluctant COVID-19 Patients Responding to Convalescent Plasma; A case series

Public title:

Severe Reluctant COVID-19 Patients Responding to Convalescent Plasma; A case series

注册题目简写:

English Acronym:

研究课题的正式科学名称:

Severe Reluctant COVID-19 Patients Responding to Convalescent Plasma; A case series

Scientific title:

Severe Reluctant COVID-19 Patients Responding to Convalescent Plasma; A case series

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

Rawezh qadr 

研究负责人:

Fahmi Hussein Kakamad 

Applicant:

Rawezh qadr 

Study leader:

Fahmi Hussein Kakamad 

申请注册联系人电话:

Applicant telephone:

+96 477 17267454

研究负责人电话:

Study leader's
telephone:

+96 477 17267454

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Rawizh.mohammed94@gmail.com

研究负责人电子邮件:

Study leader's E-mail:

Rawizh.mohammed94@gmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

Doctor city, Sulaimani, Iraq

研究负责人通讯地址:

Doctor city, Sulaimani, Iraq

Applicant address:

Doctor city, Sulaimani, Iraq

Study leader's address:

Doctor city, Sulaimani, Iraq

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

伊拉克苏莱曼尼大学

Applicant's institution:

University of Sulaimani, Sulaimani, Iraq

研究负责人所在单位:

伊拉克苏莱曼尼大学

Affiliation of the Leader:

University of Sulaimani, Sulaimani, Iraq

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

233

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Arabic board of medical specialties- Ethical committee

Name of the ethic committee:

Arabic board of medical specialties- Ethical committee

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

hiwa

Contact Name of the ethic committee:

hiwa

伦理委员会联系地址:

Doctor city, Sulaimani, Iraq

Contact Address of the ethic committee:

Doctor city, Sulaimani, Iraq

伦理委员会联系人电话:

Contact phone of the ethic committee:

+96 477 17267454

伦理委员会联系人邮箱:

Contact email of the ethic committee:

abdulwahid.salih@univsul.edu.iq

研究实施负责(组长)单位:

None

Primary sponsor:

none

研究实施负责(组长)单位地址:

None

Primary sponsor's address:

none

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

None

Source(s) of funding:

None

研究疾病:

新型冠状病毒肺炎(COVID-19)  

Target disease:

Novel Coronavirus Pneumonia (COVID-19)

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

effect of convalescent plasma on COVID  

Objectives of Study:

effect of convalescent plasma on COVID

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

COVID with convalescent plasma treatment

Inclusion criteria

COVID with convalescent plasma treatment

排除标准:

Non-covid patient

Exclusion criteria:

Non-covid patient

研究实施时间:

Study execute time:

From 2020-05-11 00:00:00 To 2020-05-19 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-05-11 00:00:00 To 2020-05-14 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

24

Group:

Case series

Sample size:

干预措施:

convalescent plasma of COVID

干预措施代码:

Intervention:

convalescent plasma of COVID

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

伊拉克

省(直辖市):

苏莱曼尼 

市(区县):

 

Country:

Iraq

Province:

Sulaimani

City:

Sulaimani

单位(医院):

苏莱曼尼大学 

单位级别:

大学 

Institution
hospital:

University of sulaimani

Level of the institution:

University

测量指标:

Outcomes:

指标中文名:

痊愈率

指标类型:

主要指标

Outcome:

Rate of cure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 45 years
最大 Max age 50 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

N/A

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Not stated

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

N/A

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Not stated

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

N/A

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-05-28 07:05:59